Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Rolontis vs Pegfilgrastim in Breast Cancer Neutropenia
NCT02643420Phase 3Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jan 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of esketamine in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Duration of Severe Neutropenia in Cycle 1. Started Jan 2016; status: completed.
02
Drugs
esketamine
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02643420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643420.